298 related articles for article (PubMed ID: 33045848)
21. Modern therapies in atopic dermatitis: biologics and small molecule drugs.
Worm M; Francuzik W; Kraft M; Alexiou A
J Dtsch Dermatol Ges; 2020 Oct; 18(10):1085-1092. PubMed ID: 32666644
[TBL] [Abstract][Full Text] [Related]
22. A mathematical model to identify optimal combinations of drug targets for dupilumab poor responders in atopic dermatitis.
Miyano T; Irvine AD; Tanaka RJ
Allergy; 2022 Feb; 77(2):582-594. PubMed ID: 33894014
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.
Guttman-Yassky E; Blauvelt A; Eichenfield LF; Paller AS; Armstrong AW; Drew J; Gopalan R; Simpson EL
JAMA Dermatol; 2020 Apr; 156(4):411-420. PubMed ID: 32101256
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy in atopic dermatitis.
Li W; Man XY
Immunotherapy; 2022 Oct; 14(14):1149-1164. PubMed ID: 36046941
[TBL] [Abstract][Full Text] [Related]
25. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
Simpson EL; Bieber T; Guttman-Yassky E; Beck LA; Blauvelt A; Cork MJ; Silverberg JI; Deleuran M; Kataoka Y; Lacour JP; Kingo K; Worm M; Poulin Y; Wollenberg A; Soo Y; Graham NM; Pirozzi G; Akinlade B; Staudinger H; Mastey V; Eckert L; Gadkari A; Stahl N; Yancopoulos GD; Ardeleanu M;
N Engl J Med; 2016 Dec; 375(24):2335-2348. PubMed ID: 27690741
[TBL] [Abstract][Full Text] [Related]
26. Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis.
Wang FP; Tang XJ; Wei CQ; Xu LR; Mao H; Luo FM
J Dermatol Sci; 2018 May; 90(2):190-198. PubMed ID: 29472119
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of biologics in atopic dermatitis.
Wu J; Guttman-Yassky E
Expert Opin Biol Ther; 2020 May; 20(5):525-538. PubMed ID: 32003247
[No Abstract] [Full Text] [Related]
28. [Status quo and prospects for systemic therapy of atopic dermatitis. Biologics ante portas].
Biedermann T; Werfel T
Hautarzt; 2015 Feb; 66(2):108-13. PubMed ID: 25645542
[TBL] [Abstract][Full Text] [Related]
29. Biologics in atopic dermatitis.
Chan S
Curr Opin Allergy Clin Immunol; 2021 Jun; 21(3):297-302. PubMed ID: 33871424
[TBL] [Abstract][Full Text] [Related]
30. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
Bansal A; Simpson EL; Paller AS; Siegfried EC; Blauvelt A; de Bruin-Weller M; Corren J; Sher L; Guttman-Yassky E; Chen Z; Daizadeh N; Kamal MA; Shumel B; Mina-Osorio P; Mannent L; Patel N; Graham NMH; Khokhar FA; Ardeleanu M
Am J Clin Dermatol; 2021 Jan; 22(1):101-115. PubMed ID: 33481203
[TBL] [Abstract][Full Text] [Related]
31. Effects of systemic therapies on pruritus in adults with atopic dermatitis: a systematic review and meta-analysis.
Tan XL; Thomas BR; Tan YJ; O'Toole EA
Clin Exp Dermatol; 2022 Apr; 47(4):658-666. PubMed ID: 34643956
[TBL] [Abstract][Full Text] [Related]
32. Emerging Systemic Therapeutic Biologics and Small Molecules for Atopic Dermatitis: How to Decide Which Treatment Is Right for Your Patients.
Ahn J; Grinich EE; Choi Y; Guttman-Yassky E; Simpson EL
J Allergy Clin Immunol Pract; 2021 Apr; 9(4):1449-1460. PubMed ID: 33838838
[TBL] [Abstract][Full Text] [Related]
33. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus.
Silverberg JI; Pinter A; Pulka G; Poulin Y; Bouaziz JD; Wollenberg A; Murrell DF; Alexis A; Lindsey L; Ahmad F; Piketty C; Clucas A
J Allergy Clin Immunol; 2020 Jan; 145(1):173-182. PubMed ID: 31449914
[TBL] [Abstract][Full Text] [Related]
34. Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors.
Kim RW; Lam M; Abuabara K; Simpson EL; Drucker AM
Am J Clin Dermatol; 2024 Mar; 25(2):179-193. PubMed ID: 38216802
[TBL] [Abstract][Full Text] [Related]
35. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
[TBL] [Abstract][Full Text] [Related]
36. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis.
Klein PA; Clark RA
Arch Dermatol; 1999 Dec; 135(12):1522-5. PubMed ID: 10606058
[TBL] [Abstract][Full Text] [Related]
37. Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis.
Serra-Baldrich E; Santamaría-Babí LF; Francisco Silvestre J
Actas Dermosifiliogr; 2022; 113(7):674-684. PubMed ID: 35842249
[TBL] [Abstract][Full Text] [Related]
38. New and Emerging Biologics for Atopic Dermatitis.
Baghoomian W; Na C; Simpson EL
Am J Clin Dermatol; 2020 Aug; 21(4):457-465. PubMed ID: 32323259
[TBL] [Abstract][Full Text] [Related]
39. Emerging treatments for itch in atopic dermatitis: A review.
Labib A; Ju T; Yosipovitch G
J Am Acad Dermatol; 2023 Aug; 89(2):338-344. PubMed ID: 37156337
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2).
Thaçi D; L Simpson E; Deleuran M; Kataoka Y; Chen Z; Gadkari A; Eckert L; Akinlade B; Graham NMH; Pirozzi G; Ardeleanu M
J Dermatol Sci; 2019 May; 94(2):266-275. PubMed ID: 31109652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
